Manufacturer
INTAS PHARMACEUTICALS LIMITED
Contents
Clopidogrel
Indication
Adult patients suffering from MI (few days until <35 days), ischaemic stroke (7 days until <6 mth) or established peripheral arterial disease; non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) ie, patients undergoing a stent placement following percutaneous coronary intervention; ST segment elevation acute MI, in combination w/ acetylsalicylic acid (ASA) in medically treated patients eligible for thrombolytic therapy. In combination w/ ASA for the prevention of atherothrombotic & thromboembolic events ie, stroke.
Instruction
May be taken with or without food.
Drug interaction
Increased risk of bleeding w/ anticoagulants, other antiplatelets, NSAIDs. Reduced drug levels by CYP2C19 inhibitors eg, proton-pump inhibitors. Ineffective inhibition of platelet aggregation w/ amiodarone. Decreased antiplatelet effect & increased risk of thrombotic events w/ amlodipine, diltiazem, felodipine, nicardipine, nimodipine, verapamil. Reduced clinical efficacy w/ chloramphenicol, cimetidine, fluconazole, fluoxetine, ketoconazole, omeprazole, ticlopidine, voriconazole. Contradictory effects of clinical efficacy reduction by fluvoxamine. Increased risk for thrombosis w/ esomeprazole, omeprazole, rabeprazole. Increased risk of tamoxifen toxicity.
Malaysia
